Brian di Donato - 16 Feb 2024 Form 4 Insider Report for Immunocore Holdings plc (IMCR)

Reporting relationship: CHIEF FINANCIAL OFFICER
Issuer ticker: IMCR
Reported as of: 16 Feb 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Feb 2024, 16:15:43 UTC
Prior SEC filing: 02 Jan 2024
Source filing: View source filing
Reporting owner signature: /s/ Lily Hepworth, Attorney-in-Fact

Key filing fact

Brian di Donato filed Form 4 for Immunocore Holdings plc (IMCR) on 21 Feb 2024.

Key facts

This page summarizes Brian di Donato's Form 4 filing for Immunocore Holdings plc (IMCR).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 21 Feb 2024, 16:15.

Change

Previous filing in this sequence was filed on 02 Jan 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IMCR transaction Derivative

Employee Share Option (Right to Buy)

Award

Transaction value: $0
Shares: +66,746
Change %
Price: $0.000000
Shares after: 66,746
Date: 16 Feb 2024
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 66,746
Exercise price: $70.50
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

25% of the shares subject to the option award shall vest on February 16, 2025, and 6.25% of the shares subject to the option award shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.